USO DE INIBIDORES DE COX-2 NO TRATAMENTO DO CARCINOMA DE CÉLULAS DE TRANSIÇÃO DE BEXIGA EM CÃES – REVISÃO
Palavras-chave:
bexiga, carcinoma de células de transição, COX-2, oncologiaResumo
Nas últimas décadas diversos estudos têm sido realizados correlacionando o desenvolvimento e progressão de alguns tipos de neoplasias com a presença da cicloxigenase-2 (COX-2) e consequentemente superprodução de prostaglandinas nas células tumorais. Os mecanismos envolvidos neste processo são a inibição da apoptose, a indução de angiogênese, o estímulo à proliferação celular, o aumento na capacidade de invasão tumoral (favorecendo os mecanismos de metástase) e a supressão do sistema imune. A partir destas observações, o uso de inibidores de COX-2 foi sugerido em alguns tipos de neoplasias especialmente no carcinoma de células de transição de bexiga. Neste contexto, o presente trabalho consiste da revisão de literatura sobre o uso de inibidores de COX-2 no tratamento do carcinoma de células de transição de bexiga em cães.
Referências
Andrade SF. Antiinflamatórios. In: Manual de terapêutica veterinária. São Paulo: Roca;
p.89-113.
Groot DJA, Vries EGE, Groen HJM, Jong S. Non-steroidal anti-inflammatory drugs to
potentiate chemotheraphy effects: from lab to clinic. Crit Rev Oncol Hematol. 2007;61:52-
Hayes A. Cancer, cyclo-oxygenase and nonsteroidal anti-inflammatory dugs – can we
combine all three? Vet Comp Oncol. 2007;5:1-13.
Mohammed SI, Khan KNM, Sellers RS, Hayec MG, De Nicola DB, Wu L, et al.
Expression of cyclooxygenase-1 and 2 in naturally occurring canine cancer. Prostaglandins
Leukot Essent Fatty Acids. 2004;70:479-83.
Clifford CA. Cancer and non-steroidal drugs. In: Proceedings of North American
Veterinary Conference; 2005, Orlando. Orlando: NAVC; 2005. p.619.
Dhawan D, Jefreys AB, Zheng R, Stewart JC, Knapp DW. Cyclooxygenase-2 dependent
and independent antitumor effects induced by celecoxib in urinary bladder cancer cells.
Mol Cancer Ther. 2008;7:897-904.
Kanaoka S, Takai T, Yoshida K. Cyclooxygenase-2 and tumor biology. Adv Clin Chem.
;43:59-78.
Morrisom WB. Non-cytotoxic drugs in cancer treatment. In: Proceedings of North
American Veterinary Conference; 2007, Ithaca. Ithaca: NAVC; 2007.
Lloret A. The use of cox-2 drugs in oncology: clinical case. In: Proceedings of Southern
European Veterinary Conference; 2008, Barcelona. Barcelona: Avepa; 2008.
Grosch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2) –
Independent anticarcinogenic effects of selective COX-2 Inhibitor. J Natl Cancer Inst.
;98:736-47.
Shyong D, Chen IH, Chang SY. The expression of cyclooxygenase in transitional cell
carcinoma cell lines: its correlation with tumor differentiation, invasiveness and
prostanoids production. Eur Urol. 2003;44:491-4.
Heller DA, Clifford CA, Goldschimidt MH, Holt DE, Manfredi MJ, Soreno KU.
Assessment of cyclooxygenase -2 expression in canine hemangiosarcoma, histiocytic
sarcoma e mast cell tumor. Vet Pathol. 2005;42:350-3.
Jang TJ, Lee KS. The expression ofcyclooxygenases-2 and surviving in urinary bladder
transitional cell carcinoma. Korean J Pathol. 2009;43:206-11.
Jones MK, Wang H, Pescar BM, Levin E, Itani RM, Sarfeh J, et al. Inhibition of
angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and
implications for cancer growth and ulcer healing. Nat Med. 1999;5:1418-23.
Macewen EG, Helfand SC. Immunology and biologic theraphy of cancer. In: Withrow
SJ, MacEwan EG. Small animal clinical oncology. 4ª ed. Philadelphia: W.B. Saunders;
p.99-111.
Knapp DW, Glickman WR, Denicola DB, Bonney PL, Tsang BS, Lawrence T, et al.
Naturally-occurring canine transitional cell carcinoma of urinary bladder: a revelant
model of human invasive bladder cancer. Urol Oncol. 2000;5:47-59.
Knapp DW, Glickman NW, Widmer WR, Denicola DB, Adams LG, Kuczec T, et al.
Cisplatin versus cisplatin combined with piroxican in a canine model of human ivasive
urinary bladder cancer. Cancer Chemother Pharmacol. 2000;46:221-6.
Mohammed SI, Bennett PF, Craig BA, Glickman NW, Mutsaer AJ, Snyder PW, et al.
Effects of the Cyclooxygenase inhibitor, Piroxican, on tumor response, apoptosis, and
angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res.
;62:356-8.
Boria PA, Glickman NW, Schimidt BR, Widmer WR, Mutsaers AJ, Adams LG, et al.
Carboplatin and piroxicam therapy in 31 dogs with transitional cell carcinoma of the
urinary bladder. Vet Comp Oncol. 2005;3:73-80.
Lee JY, Tanabe S, Shimoriha H, Kobayashi Y, Oomachi T, Azuma S, et al. Expression of
cyclooxygenase -2, P-glycoprotein and multi-drug resistance associated protein in canine
transitional cell carcinoma. Res Vet Sci. 2007;83:210-6.
Henry CJ. Transitional cell carcinoma. In: Proceedings of the 32º World Small Animal
Veterinary Association; 2007, Sydney. Sydney: Wsava; 2007.
Dhawan D, Craig BA, Cheng L, Snyder PW, Mohammed SI, Stewart JC, et al. Effects of
short-term Celecoxib treatment in patients with invasive transitional cell carcinoma of the
urinary bladder. Mol Cancer Ther. 2010;9:1371-7.
Daleck CR, De Nardi AB, Rodigheri SM, Motta FR. Neoplasia do sistema urinário. In:
Oncologia em cães e gatos. São Paulo: Roca; 2008. p.471-9.
Crow SE. Canine cancer genetics: transitional cell carcinoma in Scottish terrier. Cancer
Ther. 2008;6:177-80.
Nasir K, Khan M, Knapp DW, Denicola DB, Harris RK. Expression of cyclooxygenase-2
in transitional cell carcinoma of the urinary bladder in dog. Am J Vet Res. 2000;61:478-
Ristimaki A, Nieminem O, Saukkonen K, Hotakainem K, Nordling S, Haglund C.
Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary
bladder. Am J Pathol. 2001;158:849-53.
Wadhwa P, Goswami AK, Joshi K, Sharma SK. Cyclooxygenase-2 expression increase
with the stage and grade in transitional cell carcinoma of the urinary bladder. Int Urol
Nephrol. 2005;37:47-53.
Knapp DW, Richardson RC, Chan TC, Bottoms GD, Widmer WR, Denicola DB, et al.
Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J
Vet Intern Med. 1994;8:273-8.
MohsenI H, Zaslau S, Mcfadden D, Riggs DR, Jackson BJ, Kandzari S. COX-2 inhibiton
demonstrates potent anti-proliferative effects on bladder cancer In vitro. J Surg Res.
;119:138-42.
Henry CJ, Mccaw DL, Turnquist SE, Tyler JW, Bravo L, Sheafor S, et al. Clinical
evaluation of mitoxantrone and piroxican in a canine model of human invasive urinary
bladder carcinoma. Clin Cancer Res. 2003;9:906-11.
Mutsaers AJ, Mohammed DB, Denicola DB, Snyder PW, Glickman PF, Bennett PF, et
al. Pretreatment tumor prostaglandin E2 concentration and cyclooxygenase-2 expression
are not associated with the response of canine naturally occurring invasive urinary
bladder cancer to cyclooxygenase inhibitor therapy. Prostaglandins Leukot Essent Fatty
Acids. 2005;72:181-6.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Este obra está licenciado com uma Licença Creative Commons Atribuição-NãoComercial 4.0 Internacional.
